Trump defends use of HCQ, says it works in early stages of Covid infection

In May, Trump disclosed that he was taking daily doses of hydroxychloroquine to ward off coronavirus after consulting the White House doctor

hydroxychloroquine, hcq, drugs, coronavirus, pharma
There is no evidence that the drug can fight the virus, and regulators warn it may cause heart problems.
Press Trust of India
3 min read Last Updated : Jul 29 2020 | 11:37 AM IST
US President Donald Trump has again defended the use of hydroxychloroquine to ward off coronavirus, saying many frontline medical workers agree with him that the malaria drug works in the early stages of Covid-19 infection, despite mounting evidence that it is ineffective in treating the disease.

In May, Trump disclosed that he was taking daily doses of hydroxychloroquine to ward off coronavirus after consulting the White House doctor.

"I happen to believe in it (hydroxychloroquine). I would take it. As you know, I took it for a 14-day period, and I'm here. I happen to think it works in the early stages. I think frontline medical people believe that too -- some, many," Trump told reporters at a White House news conference on Tuesday.

"But the one thing we know: It's been out for a long time, that particular formula, and that's essentially, what it is, the pill. And it's been for malaria, lupus, and other things. It's safe. It doesn't cause problems. I had no problem. I had absolutely no problem, felt no different. Didn't feel good, bad, or indifferent. I tested, as you know. It didn't hurt me, and it's not going to hopefully hurt anybody," he said.

There is no evidence that the drug can fight the virus, and regulators warn it may cause heart problems.

Last month, the US Food and Drug Administration (FDA) cautioned against the use of the drug for treatment of the coronavirus, following reports of "serious heart rhythm problems" and other health issues.

The World Health Organization (WHO) says "there is currently no proof" that it is effective as a treatment or prevents Covid-19.

"Many doctors think hydroxychloroquine is extremely successful: the hydroxychloroquine coupled with the zinc and perhaps the azithromycin.. But many doctors think it's extremely good, and some people don't. I think it's become very political," Trump said referring to the controversy surrounding the malaria drug.

"We know from that standpoint - because it's been so many years, from a safety standpoint, it's safe. I happen to think, based on what I've read - I've read a lot about hydroxy. I happen to think that it has an impact, especially in the early years. There were some very good tests at Ford, and the doctor from Yale came up with a very, very strong testament to it," he said.

There are no FDA-approved drugs for the coronavirus, which has infected more than 16 million people worldwide and killed at least 655,300, according to data compiled by Johns Hopkins University.


More than 150,000 Americans have died because of coronavirus and over 4.4 million have tested positive.

Hydroxychloroquine sulfate was first synthesised in 1946 and is in a class of medications historically used to treat and prevent malaria. It is approved by the US Food and Drug Administration to treat malaria, rheumatoid arthritis, lupus, childhood arthritis, and other autoimmune diseases.

The drug generated excitement earlier in the year after small studies suggested it could be beneficial, especially when combined with antibiotic azithromycin. Trump promoted it as a potential treatment for the virus and said he used it as a preventive measure against the disease. However, several larger studies showed the drug was not helpful and caused heart issues in some patients.

The drug is not FDA-approved for the treatment of Covid-19 but it has been identified as a possible treatment for the infection and the US government has requested its immediate availability.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :HydroxychloroquineCoronavirusCoronavirus VaccineDonald Trump

Next Story